Neoadjuvant chemotherapy for pediatric osteosarcoma patients

Cancer

Volumn 79, Issue 2, 1997, Pages 411-415

  Uchida, Atsumasa ^a,b   Myoui, Akira ^a   Araki, Nobuto ^a   Yoshikawa, Hideki ^a   Shinto, Yoshitaka ^a   Ueda, Takafumi ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b MIE UNIVERSITY   (Japan)

Author keywords

dose intensity; neoadjuvant chemotherapy; osteosarcoma; pediatric tumors

Indexed keywords

BICARBONATE; CISPLATIN; DOXORUBICIN; FOLINATE CALCIUM; IFOSFAMIDE; METHOTREXATE;

ADOLESCENT; ADULT; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER SURVIVAL; CHILD; CLINICAL FEATURE; DRUG MEGADOSE; FEMALE; HISTOLOGY; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; INTRABRONCHIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIMB SALVAGE; MAJOR CLINICAL STUDY; MALE; OSTEOSARCOMA; PRIORITY JOURNAL; RADIODIAGNOSIS; RETROSPECTIVE STUDY;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CHILD; CHILD, PRESCHOOL; CISPLATIN; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; IFOSFAMIDE; MALE; METHOTREXATE; OSTEOSARCOMA; RETROSPECTIVE STUDIES;

EID: 0031014589     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970115)79:2<411::AID-CNCR26>3.0.CO;2-2     Document Type: Article

References (16)

1. Jaffe N, Frei E, Traggis D, Watts H. Weekly high dose methotrexate-citrovorum factor in osteogenic sarcoma. Cancer 1977;39:45-50.
2. Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop 1980;153:106-20.
3. Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984;2:1281-8.
4. Tannock IF, Boyd NF, DeBoer G, Erlichman C, Fine S, Larocque G, et al. A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol 1988;6:1377-87.
5. Kwak LW, Halpern J, Olshen A, Homing SJ. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of three structured survival analysis. J Clin Oncol 1990;8:963-77.
6. Klassa RJ, Murray N, Coldman AJ. Dose-intensity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung. J Clin Oncol 1991;9:499-508.
7. Link MP, Goorin AM, Miser AW, Green AA, Pratt CB, Belasco JB, et al. The effect of adjuvant chemotherapy on relapse free survival in patients with osteosarcoma of the extremity. N Engl J Med 1986;314:1600-6.
8. Livingston RB. Dose intensity and high dose therapy. Cancer 1994; 74(Suppl): 1177-83.
9. Bacci G, Picci P, Avella M, Dallari D, Ferrari S, Prasad R, et al. The importance of dose-intensity in neoadjuvant chemotherapy of osteosarcoma: a retrospective analysis of high-dose methotrexate, cisplatinum and adriamycin used preoperatively. J Chemother 1990;2:127-35.
10. Bacci G, Picci P, Ferrari S, Casadei R, Brach-Del-Prever A, Tienghi A, et al. Influence of adriamycin dose in the outcome of patients with osteosarcoma treated with multidrug neo-adjuvant chemotherapy: results of two sequential studies. J Chemother 1993;5:237-46.
11. Smith MA, Ungerleider RS, Horowitz ME, Simon R. Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing's sarcoma. J Natl Cancer Inst 1992;84:202-4.
12. Pratt CB, Champion JE, Fleming ID, Rao B, Kumar AP, Evans WE, et al. Adjuvant chemotherapy for osteosarcoma of the extremity. Long-term results of two consecutive prospective protocol studies. Cancer 1990;65:439-45.
13. Winkler K, Beron G, Delling G, Heise U, Kabisch C, Purfurst C, et al. Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histologica) tumor response. J Clin Oncol 1988;6:329-37.
14. Rosen G, Caparros B, Huvos AG, Kosloff C, Nirenberg A, Cacavio A, et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 1982;49:1221-30.
15. Antman KH, Ryan L, Elias A, Sherman D, Grier HE. Response to ifosfamide and mesna: 124 previously treated patients with metastatic unresectable sarcoma. J Clin Oncol 1989;7:126-31.
16. Antman KH, Crowley J, Balcerzak SP, Rivkin SE, Weiss GR, Elias A, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcoma. J Clin Oncol 1993;11:1276-85.